Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Elraglusib |
Synonyms | |
Therapy Description |
9-ING-41 is an ATP-competitive inhibitor that selectively blocks GSK-3beta, potentially leading to cell cycle arrest and apoptosis, inhibition of tumor cell proliferation, and decreased tumor growth (PMID: 31894292, PMID: 29846250). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Elraglusib | 9 ING 41|9-ING-41 | GSK-3beta Inhibitor 4 | Elraglusib is an ATP-competitive inhibitor that selectively blocks GSK-3beta, potentially leading to cell cycle arrest and apoptosis, inhibition of tumor cell proliferation, and decreased tumor growth (PMID: 31894292, PMID: 29846250). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03678883 | Phase Ib/II | Carboplatin + Elraglusib + Paclitaxel Elraglusib + Irinotecan Doxorubicin + Elraglusib Elraglusib + Lomustine Carboplatin + Elraglusib Elraglusib + Gemcitabine + Nab-paclitaxel Elraglusib Elraglusib + Gemcitabine | 9-ING-41 in Patients With Advanced Cancers | Active, not recruiting | USA | NLD | FRA | ESP | CAN | BEL | 1 |
NCT04239092 | Phase I | Elraglusib + Irinotecan Elraglusib | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Recruiting | USA | 0 |